Edgewise Q1 net loss $49M, cash $499.6M; sevasemten Becker data up to 3.5 years

Edgewise Therapeutics, Inc.

2026-Q1 EPS reported -$0.46

Net loss $49.0M ($0.46/share) in Q1 2026 vs $40.8M ($0.43/share) in Q1 2025; cash and equivalents $499.6M.
R&D expense $42.7M (up 16% YoY) driven by EDG-7500 and EDG-15400 clinical activity, partly offset by lower sevasemten costs.
Long-term MESA OLE data shows sevasemten stabilizes function in Becker up to 3.5 years; 99% enrollment from prior trials.
Pivotal GRAND CANYON sevasemten top-line results expected Q4 2026; marketing application planned H1 2027.
CIRRUS-HCM Part D (EDG-7500) 12-week data in HCM expected Q2 2026; Phase 3 initiation H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edgewise Therapeutics, Inc. reported financial results for first quarter of 2026.

Period: first quarter of 2026
Result: reported results

Exact text from the filing

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.

View on SEC.gov

Browse all earnings releases →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-056783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.